Comparative proteomic profiling of sera from patients with refractory multiple myeloma reveals potential biomarkers predicting response to bortezomib-based therapy

Real-life experience with bortezomib-based regimens in elderly comorbid patients with newly diagnosed multiple myeloma – Polish retrospective multicenter analysis

“…The development of new biomarkers predicting response to therapy would allow an identification of patients who should receive other first -line therapeutic regimens as the first -line treatment. [18][19][20] As in the previous reports, impaired renal function did not have negative impact on the response rates or PFS. Importantly, patients who responded to therapy showed an improvement in renal function, confirming the efficacy of this protocol in patients with renal failure.…”

Apolipoprotein C1: Its Pleiotropic Effects in Lipid Metabolism and Beyond

“…Furthermore, apoC1 was also reported as a marker for Wilms tumor [197], gastric adenocarcinoma [198], refractory multiple myeloma [199], hepatitis B-related hepatocellular carcinoma [200].…”

Proteomic analysis of serum for identification of potential biomarkers predicting response of patients with refractory multiple myeloma to bortezomib‑based therapy

“…[6][7][8] Bone marrow plasma cells are obtained by an invasive method of bone marrow biopsy, which is not useful in routine clinical practice. Therefore, Łuczak et al 4 have used proteomic analysis of se rum to overcome this obstacle. They used nano liquid chromatography-tandem mass spectrom etry to analyze digested serum protein samples from 61 proteasome inhibitor naive, transplant eligible patients with MM, who were resistant to the first line chemotherapy protocol CTD (cyclo phosphamide, thalidomide, and dexamethasone) and were scheduled for salvage PAD (bortezo mib, adriamycin [doxorubicin], and dexameth asone) or VTD (bortezomib, thalidomide, and dexamethasone) chemotherapy.…”